575
Views
14
CrossRef citations to date
0
Altmetric
Review

An updated patent review of autotaxin inhibitors (2017–present)

, , , &
Pages 421-434 | Received 17 Sep 2020, Accepted 17 Dec 2020, Published online: 12 Jan 2021

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Sehrish Bano, Mariya Al-Rashida, Rima D Alharthy, Imtiaz Ali Khan & Jamshed Iqbal. (2022) Nucleotide pyrophosphatase/phosphodiesterases (NPPs) including NPP1 and NPP2/ ATX as important drug targets: A patent review (2015-2020). Expert Opinion on Therapeutic Patents 32:7, pages 743-751.
Read now

Articles from other publishers (13)

Xuan Li, Yuan Zhang, Tengjiang Zhang, Luyang Zhao, Christopher G. Lin, Haitian Hu & Hanqiu Zheng. (2023) Tafazzin mediates tamoxifen resistance by regulating cellular phospholipid composition in ER-positive breast cancer. Cancer Gene Therapy.
Crossref
Namrashee V. Mehta, Arundhati Abhyankar & Mariam S. Degani. (2023) Elemental exchange: Bioisosteric replacement of phosphorus by boron in drug design. European Journal of Medicinal Chemistry 260, pages 115761.
Crossref
Ling Yang, Pei Shu, Nan Wu, Mengyue Hu & Zhu Luo. (2023) Pharmacokinetics, pharmacodynamics, safety and tolerability of FTP-198, a novel, selective Autotaxin inhibitor, in healthy subjects: A phase I randomized placebo-controlled trial. European Journal of Pharmaceutical Sciences 189, pages 106552.
Crossref
Matthew G. K. Benesch, Rongrong Wu, Xiaoyun Tang, David N. Brindley, Takashi Ishikawa & Kazuaki Takabe. (2023) Lysophosphatidic Acid Receptor Signaling in the Human Breast Cancer Tumor Microenvironment Elicits Receptor-Dependent Effects on Tumor Progression. International Journal of Molecular Sciences 24:12, pages 9812.
Crossref
Elli-Anna Stylianaki, Christiana Magkrioti, Eleni M. Ladopoulou, Konstantinos D. Papavasileiou, Panagiotis Lagarias, Georgia Melagraki, Martina Samiotaki, George Panayotou, Skarlatos G. Dedos, Antreas Afantitis, Vassilis Aidinis & Alexios N. Matralis. (2023) “Hit” to lead optimization and chemoinformatic studies for a new series of Autotaxin inhibitors. European Journal of Medicinal Chemistry 249, pages 115130.
Crossref
Yu-Ting Chen, Cong Zhou, Zeng-Bao Yang & Guo-Bo Li. 2023. Privileged Scaffolds in Drug Discovery. Privileged Scaffolds in Drug Discovery 335 355 .
Nicholas A. Meanwell & Olivier Loiseleur. (2022) Applications of Isosteres of Piperazine in the Design of Biologically Active Compounds: Part 2. Journal of Agricultural and Food Chemistry 70:36, pages 10972-11004.
Crossref
Theodosis Kalamatianos, Evangelos Drosos, Christiana Magkrioti, Ioanna Nikitopoulou, Christos Koutsarnakis, Anastasia Kotanidou, George P. Paraskevas, Vassilis Aidinis & George Stranjalis. (2022) Autotaxin Activity in Chronic Subdural Hematoma: A Prospective Clinical Study. Diagnostics 12:8, pages 1865.
Crossref
A. A. Schegoleva, A. A. Khozyainova, T. S. Gerashchenko, L. D. Zhuikova & Evgeny V. Denisov. (2022) Metastasis prevention: targeting causes and roots. Clinical & Experimental Metastasis 39:4, pages 505-519.
Crossref
Sha She, Qian Zhang, Jinzhi Shi, Fan Yang & Kai Dai. (2022) Roles of Autotaxin/Autotaxin-Lysophosphatidic Acid Axis in the Initiation and Progression of Liver Cancer. Frontiers in Oncology 12.
Crossref
Ángela Gento‐Caro, Esther Vilches‐Herrando, Federico Portillo, David González‐Forero & Bernardo Moreno‐López. (2021) Targeting autotaxin impacts disease advance in the SOD1‐G93A mouse model of amyotrophic lateral sclerosis. Brain Pathology 32:3.
Crossref
Lynn Bitar, Timo Uphaus, Carine Thalman, Muthuraman Muthuraman, Luzia Gyr, Haichao JiMicaela DominguesHeiko Endle, Sergiu GroppaFalk Steffen, Nabin Koirala, Wei Fan, Laura Ibanez, Laura Heitsch, Carlos Cruchaga, Jin-Moo Lee, Florian Kloss, Stefan Bittner, Robert NitschFrauke Zipp & Johannes Vogt. (2022) Inhibition of the enzyme autotaxin reduces cortical excitability and ameliorates the outcome in stroke. Science Translational Medicine 14:641.
Crossref
Daniel S. Glass, David Grossfeld, Heather A. Renna, Priya Agarwala, Peter Spiegler, Joshua DeLeon & Allison B. Reiss. (2022) Idiopathic pulmonary fibrosis: Current and future treatment. The Clinical Respiratory Journal 16:2, pages 84-96.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.